Skip to content
PeptideHormone

Cagrilintide vs Eloralintide

A long-acting amylin analog built for once-weekly dosing and GLP-1 pairing. A selective, long-acting amylin agonist that reaches GLP-1-class weight loss without touching the GLP-1 receptor. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.

Cagrilintide
Eloralintide
Also known as——
TypeAnalogAnalog
EvidenceInvestigationalInvestigational
FamilyIncretins & metabolicIncretins & metabolic
ClassLong-acting amylin analog (acylated peptide)Selective long-acting amylin analog (acylated 37 aa peptide)
Receptor / targetAmylin receptors (calcitonin receptor + RAMP)Amylin receptors (calcitonin receptor + RAMP), AMY1-selective
Molecular weight~4,408.9 Da~4,526 Da
Half-life
~7 days (159-195 h)
Model dosing
~13–15 days (310–366 h)
Model dosing
Based onAmylinAmylin

Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.

Common questions

What is the difference between Cagrilintide and Eloralintide?
Cagrilintide is an engineered analog based on Amylin; Eloralintide is an engineered analog based on Amylin. Cagrilintide signals at Amylin receptors (calcitonin receptor + RAMP); Eloralintide signals at Amylin receptors (calcitonin receptor + RAMP), AMY1-selective.
How do the half-lives of Cagrilintide and Eloralintide compare?
The reported circulating half-life of Cagrilintide is ~7 days (159-195 h); Eloralintide is ~13–15 days (310–366 h). These are reference values for the native or representative form — educational only, not dosing advice.

Prefer the other order? Eloralintide vs Cagrilintide. Or open the interactive comparison tool to add more molecules.